Co-occurrence of myositis and neuropathy after anti-CD30 therapy in a late-adolescent Hodgkin lymphoma patient

Abstract Objective Immune-related adverse events (irAEs) are recognized in oncology, particularly with immune checkpoint inhibitors and other targeted therapies. Brentuximab Vedotin (BV), is an anti-CD30 antibody–drug conjugate- its association with immune-mediated myositis remains unexplored. We re...

詳細記述

書誌詳細

出版年:	Acta Neuropathologica Communications
主要な著者:	Adela Della Marina, Lydia Rink, Andreas Hentschel, Michael M. Schündeln, Christopher Nelke, Heike Kölbel, Calvin Tucht, Vera Dobelmann, Tobias Ruck, Tim Hagenacker, Teresinha Evangelista, Ulrike Schara-Schmidt, Andreas Roos
フォーマット:	論文
言語:	英語
出版事項:	BMC 2025-06-01
主題:	Myositis Anti-CD30 Brentuximab vedotin Chemotherapy Hodgkin lymphoma
オンライン･アクセス:	https://doi.org/10.1186/s40478-025-02056-2